ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 10 Issue 2, Summer/Fall 1996 Special Commemorative Issue

August 13, 1996

DCT Board Approves Concept For BRMP Master Agreement

June 26, 1987

In Brief: Eppley Is The “New” Center Getting an NCI Core; USC Appoints Jones Basic Science Chief

May 4, 1984

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

September 4, 1992

SWOG Plans Increase in Payments to Centers for Trial Accrual.

May 25, 2007

Consolidation Unlikely to Save Money

December 17, 2010